Stock XOMAO XOMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 10:39:44 17/05/2024 pm IST 		5-day change 1st Jan Change
25.1 USD 0.00% Intraday chart for XOMA Corporation 0.00% -0.08%
09/05 Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M MT
09/05 XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 266.4 486.4 235.8 210.7 212.5 298.6 - -
Enterprise Value (EV) 1 266.4 486.4 235.8 210.7 212.5 298.6 298.6 298.6
P/E ratio -119 x 56.6 x 32.1 x -9.29 x -4.58 x -11.2 x -15.7 x -34.2 x
Yield - - - - - - - -
Capitalization / Revenue 14.5 x 16.6 x 6.18 x 35 x 44.7 x 13 x 12.6 x 8.58 x
EV / Revenue 14.5 x 16.6 x 6.18 x 35 x 44.7 x 13 x 12.6 x 8.58 x
EV / EBITDA -69 x 39.1 x 13.4 x -12.1 x -5.19 x -16 x -19.4 x -49.8 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 9,758 11,022 11,311 11,451 11,488 11,639 - -
Reference price 2 27.30 44.13 20.85 18.40 18.50 25.66 25.66 25.66
Announcement Date 10/03/20 10/03/21 08/03/22 09/03/23 08/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 18.37 29.38 38.16 6.027 4.758 22.9 23.77 34.8
EBITDA 1 -3.86 12.44 17.54 -17.41 -40.95 -18.7 -15.4 -6
EBIT 1 -3.885 12.42 17.53 -17.41 -41.85 -7 -8 0.05
Operating Margin -21.15% 42.25% 45.94% -288.93% -879.53% -30.57% -33.66% 0.14%
Earnings before Tax (EBT) 1 -1.982 11.8 15.89 -17.12 -40.83 -16.7 -19.85 -10.55
Net income 1 -1.982 8.793 7.787 -22.58 -46.3 -26.6 -19.4 -8.867
Net margin -10.79% 29.92% 20.41% -374.58% -973.16% -116.16% -81.63% -25.48%
EPS 2 -0.2300 0.7800 0.6500 -1.980 -4.040 -2.283 -1.630 -0.7500
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 10/03/20 10/03/21 08/03/22 09/03/23 08/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 35.94 3.107 0.983 0.451 1.486 0.437 1.658 0.83 1.833 1.49 8.85 5.8 6.7
EBITDA 1 30.37 -2.063 -4.766 -4.368 -6.21 -9.944 -5.732 -5.563 -19.71 -7.002 -5 -4.6 -3.8
EBIT 1 30.36 -2.065 -4.767 -4.372 -6.21 -10.17 -5.957 -5.787 -19.93 -7.004 1.5 -1.5 0.1
Operating Margin 84.48% -66.46% -484.94% -969.4% -417.9% -2,327.23% -359.29% -697.23% -1,087.51% -470.07% 16.95% -25.86% 1.49%
Earnings before Tax (EBT) 1 29.94 -2.28 -4.67 -4.178 -5.991 -9.813 -5.4 -5.509 -20.11 -8.595 -1.3 -4.2 -2.5
Net income 1 19.74 -3.648 -6.038 -5.546 -7.344 -11.18 -6.768 -6.877 -21.48 -9.963 -4.6 -6.8 -5.55
Net margin 54.93% -117.41% -614.24% -1,229.71% -494.21% -2,558.58% -408.2% -828.55% -1,171.69% -668.66% -51.98% -117.24% -82.84%
EPS 2 1.670 -0.3200 -0.5300 -0.4800 -0.6400 -0.9800 -0.5900 -0.6000 -1.870 -0.8600 -0.3950 -0.5800 -0.4700
Dividend per Share - - - - - - - - - - - - -
Announcement Date 08/03/22 05/05/22 04/08/22 03/11/22 09/03/23 09/05/23 08/08/23 07/11/23 08/03/24 09/05/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 10/03/20 10/03/21 08/03/22 09/03/23 08/03/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for XOMA Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.66 USD
Average target price
58 USD
Spread / Average Target
+126.03%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 104B
BIONTECH SE Stock BioNTech SE
-14.15% 22.41B
ARGENX SE Stock argenx SE
-1.05% 22.28B
GENMAB A/S Stock Genmab A/S
-5.29% 19.07B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 17.89B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 14.28B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 12.55B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XOMA Stock
  4. XOMAO Stock
  5. Financials XOMA Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW